17.56
1.12 (6.81%)
| Penutupan Terdahulu | 16.44 |
| Buka | 16.96 |
| Jumlah Dagangan | 17,744,200 |
| Purata Dagangan (3B) | 19,085,512 |
| Modal Pasaran | 34,493,599,744 |
| Harga / Jualan (P/S) | 16.29 |
| Harga / Buku (P/B) | 3.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 19 Aug 2025 |
| Margin Keuntungan | -22.88% |
| Margin Operasi (TTM) | -5.25% |
| EPS Cair (TTM) | -0.280 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 129.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 22.83% |
| Nisbah Semasa (MRQ) | 7.84 |
| Aliran Tunai Operasi (OCF TTM) | -224.98 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -1.91 B |
| Pulangan Atas Aset (ROA TTM) | -2.63% |
| Pulangan Atas Ekuiti (ROE TTM) | -4.24% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (HK) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | INNOCARE | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.25 |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| INNOCARE | 34 B | - | - | 3.34 |
| BEONE MEDICINES | 297 B | - | 636.13 | 8.80 |
| HENLIUS | 35 B | - | 38.59 | 10.07 |
| ASCENTAGE-B | 24 B | - | - | 30.37 |
| EVEREST MED | 16 B | - | - | 3.45 |
| AKESO | 111 B | - | - | 15.36 |
|
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 23.48% |
| % Dimiliki oleh Institusi | 36.27% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |